Synapse - Works

Results (2146)

Ubamatamab (MUC16XCD3 bispecific antibody) with or without cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase 1 clinical and biomarker results

Meeting Abstract

Liu, J.; O'Malley, D.; Van Nieuwenhuysen, E.; Moore, K.; Hamilton, E.; Yeku, O.; Bouberhan, S.; Hou, J.; Schröder, D.; Wang, B.; more...
International Journal of Gynecological Cancer (2023)

Fulltext@MSK | Save

Durvalumab with paclitaxel/carboplatin + bevacizumab then maintenance durvalumab, bevacizumab + olaparib in patients with newly diagnosed advanced ovarian cancer without a tumour brca1/2 mutation: Results from the DUO-O/ENGOT-OV46/AGO-OVAR 23/GOG-3025 trial

Meeting Abstract

Marth, C.; Park-Simon, T. W.; Aghajanian, C.; Reuss, A.; Nishio, S.; Lim, M. C.; Rubio-Pérez, M. J.; Vardar, M. A.; Scambia, G.; Sabatier, R.; more...
International Journal of Gynecological Cancer (2023)

Fulltext@MSK | Save

Efficacy and safety of avutometinib plus defactinib in recurrent low-grade serous ovarian cancer following prior systemic therapy

Meeting Abstract

Grisham, R.; Aghajanian, C.; Van Nieuwenhuysen, E.; Rodrigues, M.; Ring, K.; Santin, A.; Colombo, N.; Prendergast, E.; Thaker, P.; Moore, K.; more...
International Journal of Gynecological Cancer (2023)

Fulltext@MSK | Save

Oncologic outcomes of sentinel lymph node mapping versus lymph node dissection in staging of apparent uterine-confined clear cell carcinoma

Meeting Abstract

Dagher, C.; Sassine, D.; Abu-Rustum, N. R.; Mueller, J. J.; Borach, V.; Zivanovic, O.; Sonoda, Y.; Friedman, C.; Leitao, M. M.
International Journal of Gynecological Cancer (2023)

Fulltext@MSK | Save

Initial Efficacy and Safety Results from ENGOT-Ov60/GOG-3052/ramp 201: A phase 2 study of avutometinib (vs-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC)

Meeting Abstract

Banerjee, S. N.; Ring, K. L.; Van Niewenhuysen, E.; Fabbro, M.; Aghajanian, C.; Oaknin, A.; Colombo, N.; Santin, A. D.; Clamp, A. R.; Moore, K. N.; more...
International Journal of Gynecological Cancer (2023)

Fulltext@MSK | Save

DB-1303, a HER2-targeting ADC, for patients with advanced/metastatic endometrial cancer: Preliminary clinical results from an ongoing phase 1/2A Trial (NCT05150691)

Meeting Abstract

Moore, K.; Makker, V.; Yeku, O.; Pothuri, B.; Growden, W.; Hamilton, E.; Musa, F.; Wang, L.; Li, X.; Godbee, N.; more...
International Journal of Gynecological Cancer (2023)

Fulltext@MSK | Save

Long-term follow up of selinexor maintenance for patients with TP53wt advanced or recurrent endometrial cancer: A pre-specified subgroup analysis from the phase 3 Engot-En5/ GOG-3055/SIENDO Study

Meeting Abstract

Fidalgo, A. P.; Vergote, I.; Hamilton, E.; Valabrega, G.; Van Gorp, T.; Sehouli, J.; Klat, J.; Levy, T.; Welch, S.; Richardson, D. L.; more...
International Journal of Gynecological Cancer (2023)

Fulltext@MSK | Save

Germline pathogenic variants and genetic counseling by ancestry in patients with epithelial ovarian cancer

Journal Article

Sia, T. Y.; Maio, A.; Kemel, Y. M.; Arora, K. S.; Gordhandas, S. B.; Kahn, R. M.; Salo-Mullen, E. E.; Sheehan, M. A.; Tejada, P. R.; Bandlamudi, C.; more...
JCO Precision Oncology (2023)

Fulltext@MSK | Save

Prevalence and clinical implications of mismatch repair-proficient colorectal cancer in patients with Lynch syndrome

Journal Article

Ranganathan, M.; Sacca, R. E.; Trottier, M.; Maio, A.; Kemel, Y.; Salo-Mullen, E.; Catchings, A.; Kane, S.; Wang, C.; Ravichandran, V.; more...
JCO Precision Oncology (2023)

Fulltext@MSK | Save

Phase IIa study of PLX2853 in gynecologic cancers with known ARID1A mutation and phase Ib/IIa study of PLX2853/carboplatin in platinum-resistant epithelial ovarian cancer

Journal Article

Duska, L. R.; Zamarin, D.; Hamilton, E.; Oza, A.; Fleming, G.; Spira, A.; Yeku, O. O.; Richardson, D. L.; Walling, J.; Inokuchi, K.; more...
JCO Precision Oncology (2023)

Fulltext@MSK | Save